Additional analyses of the two trials presented at 2023 ESC Congress
High-dose omega-3 fatty acid conferred no outcomes benefit over corn oil in high-risk patients
Perspectives and learnings from our Heart, Vascular & Thoracic Institute
Q&A with the director of our Center for Clinical Research and C5Research group
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Potential of CETP inhibitors in patients with AA genotype must await outcome trial
Celecoxib has least impact, followed by naproxen and ibuprofen
ACCELERATE substudy shows no benefit of evacetrapib in patients with diabetes
But no difference in survival if there is no dysfunction
Can’t-miss studies from SPIRE to ABSORB III and more
Once-promising HDL-targeted therapy fails to show plaque regression